5T MRI and Metabolomics to Predict Hemorrhage Risk in Moyamoya Disease
Official title: Development and Validation of a Hemorrhage Risk Prediction Model for Moyamoya Disease Based on 5T MRI and Metabolomic Features: A Prospective Cohort Study
Run by Beijing Hospital · NCT07781579 · Data updated 2026-11-12
This study tests whether advanced 5T MRI imaging and metabolomics can help predict which moyamoya patients are at higher risk of intracranial hemorrhage.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Beijing Hospital Government |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | February 1, 2026 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | August 24, 2026 |
| Trial ID | NCT07781579 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with Moyamoya disease or moyamoya syndrome confirmed by DSA who can safely undergo 5.0T MRI.
✕Probably not a fit
Patients unable to undergo 5.0T MRI or without detectable hemorrhage risk markers may derive little direct benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective cohort study will enroll patients with Moyamoya disease or moyamoya syndrome confirmed by DSA at Beijing Hospital. Participants will undergo preoperative 5.0T brain MRI including TOF-MRA, 4D MRA, high-resolution vessel wall imaging, 3D arterial spin labeling, and standard sequences, along with blood and urine metabolomics. The goal is to identify imaging and metabolic markers associated with hemorrhage risk by correlating them with hemorrhagic outcomes. The study leverages high-field imaging to quantify collateral vessel morphology and vessel-wall features, alongside metabolomic pathways linked to angiogenesis. As an observational study, it will not assign an intervention but aims to improve risk stratification for future management decisions.
Why it matters
Potential benefit: If successful, the study could improve prediction of hemorrhage risk in Moyamoya patients, informing surveillance and treatment decisions.
How similar studies have gone: Previous work suggests imaging and metabolomics can reveal disease-related patterns, but high-field 5.0T MRI for hemorrhage risk prediction in Moyamoya is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Moyamoya disease or moyamoya syndrome confirmed by digital subtraction angiography (DSA). * Able to undergo a 5.0T magnetic resonance imaging (MRI) examination. Exclusion Criteria: * Claustrophobia or any other condition precluding completion of imaging acquisition. * Previous revascularization surgery in both cerebral hemispheres. * Any intracranial hemorrhage event within 1 month before enrollment.
Where it's running
-
Beijing Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: Shaosen Zhang, MD
- Email: longyoubafang@hotmail.com
- Phone: +86 18611284839
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Endovascular devices for brain aneurysm treatment
This project tests how well newer endovascular devices work and how safe they are for people having endovascular treatment for brain aneurysms.
-
Combined cognitive and motor training for people with stroke or Moyamoya disease
This trial will test whether combined cognitive-motor training helps people with post-stroke cognitive impairment or Moyamoya disease improve their thinking and movement.
-
Deep phenotyping to explore recovery in young adults after stroke
This project will test whether a detailed health and sample-collection approach (deep phenotyping) is practical and acceptable for people aged 18–55 who have had a stroke.
-
Thrombolysis for stroke patients on Factor Xa inhibitors
This study is testing if a common stroke treatment can safely help patients who have taken certain blood thinners in the last two days.
-
Stem cell therapy for chronic stroke recovery
This study is testing whether using a patient's own stem cells can help people with long-term stroke recovery feel better and improve their daily functioning.
-
Using a digital twin app to support people in secondary prevention after stroke, Moyamoya disease, or cerebral amyloid angiopathy
This trial will try the STRATIF-AI app plus usual secondary prevention care to see if it improves daily self-care and the patient experience for adults after stroke, Moyamoya disease, or CAA.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.